NO344698B1 - Novel fish virus - Google Patents
Novel fish virus Download PDFInfo
- Publication number
- NO344698B1 NO344698B1 NO20180836A NO20180836A NO344698B1 NO 344698 B1 NO344698 B1 NO 344698B1 NO 20180836 A NO20180836 A NO 20180836A NO 20180836 A NO20180836 A NO 20180836A NO 344698 B1 NO344698 B1 NO 344698B1
- Authority
- NO
- Norway
- Prior art keywords
- seq
- sequences
- sequence
- virus
- nucleic acid
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 53
- 241000251468 Actinopterygii Species 0.000 title description 30
- 150000007523 nucleic acids Chemical group 0.000 claims description 39
- 230000000295 complement effect Effects 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 19
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 17
- 238000012163 sequencing technique Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 108010041986 DNA Vaccines Proteins 0.000 claims description 5
- 229940021995 DNA vaccine Drugs 0.000 claims description 4
- 241000277263 Salmo Species 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 229940124551 recombinant vaccine Drugs 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000019688 fish Nutrition 0.000 description 31
- 150000001413 amino acids Chemical group 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000002816 gill Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 241000244206 Nematoda Species 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000252233 Cyprinus carpio Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001436114 Piscine orthoreovirus Species 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000507462 Candidatus Branchiomonas Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000983637 Fisavirus 1 Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 241001386813 Kraken Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000098783 Neoparamoeba perurans Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000476949 Paranucleospora theridion Species 0.000 description 1
- 241000394671 Pasteurella skyensis Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000192126 Piscirickettsia salmonis Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241001001685 Salmon gill poxvirus Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241001542930 Tenacibaculum maritimum Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- -1 organic solvents Chemical class 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Novel Fish Virus
The present invention relates to use of a novel virus for vaccines and prophylactic treatment for a disease caused by the virus. The invention also relates to nucleic acid sequences, amino acid sequences, primers and primer pairs, probes and methods for diagnostic according to the preamble of the independent patent claims
Fish are an increasingly important source of food and income; global annual consumption is projected to rise from 110 million tons in 2010 to more than 200 million tons in 2030. However, the emergence of infectious diseases in aquaculture threatens production and may also impact wild fish populations.
During summer 2017 it was discovered particularly high mortality in several cages in a fish farm in Scotland. A novel fish virus was characterized from samples of the fish.
The novel virus was isolated in a salmon farm with high losses caused by disease. The virus shows unique characters and 28% similarity to unclassified Fisavirus1, that has previously been identified in Carp (Cyprinus carpio) (Reuter 2016). The sequence of Fisavirus is 8712 NT long and relates to Posavirus (Porcine stool associated virus), and it is assumed that the host of Fisavirus could be the Nematoda phylum (Reuter 2016). Nematodes (Nematoda) belong to the most frequent and the most important parasites of fishes in the freshwater, brackish-water and marine environments throughout the world (Moravec 2007). Small numbers of nematodes often occur in healthy fish, but high numbers cause illness or even death (Roy P. Yanong). Thus it is expected that the novel virus may have a broad range of hosts among fish and shellfish, such as shrimp, carp, tilapia, seabass and salmon, among others.
There is therefore a need for a rapid method to identify the virus, and a tool to monitor the production of virus and avoid outbreak. The present invention as described below, identifies the novel virus from fish, and describes methods for identification, detection and vaccine development. Another object is to develop further treatment to treat infected fish.
The virus may also be used in challenge methods using a virus according to the invention for testing susceptibility of animals, with the purpose of testing for instance efficacy of a vaccine or functional feed, or resistance towards disease. Further, the virus may be used in breeding programs to obtain animals that are resistant to the virus as defined above.
The new virus is isolated from Atlantic salmon.
The invention relates to an isolated nucleic acid sequence originating from the virus. The sequence is selected from the group consisting of SEQ ID No 2 and 3 and sequences complementary to any of SEQ ID No 2 and 3, and variants thereof being at least 70% identical.
The isolated nucleic acid sequence may further be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 or 3, or any sequences being complementary to SEQ ID No 2 or 3.
In another aspect of the invention, it relates to a nucleic acid sequence of at least 10 nucleotides, wherein said sequence hybridizes specifically to a nucleic acid sequence having a sequence selected from the group consisting of. SEQ ID No 4-12, sequences being complementary to SEQ ID No 4-12, and variants being at least 70 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to the variants of SEQ ID NO 4-12. Such a nucleic acid may be used as a primer for instance for PCR or a probe for instance for identification of a nucleic acid sequence or gene. Further, the said nucleotide sequence may be at least 15 or at least 20 nucleotides long.
In another aspect the invention provides a primer or probe comprising a sequence selected from the group consisting of SEQ ID NO 4-12, sequences being complementary to SEQ ID NO 4-12, and variants being at least 90 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to the variants of SEQ ID NO 4-12. In some aspects the primer may be 15 nucleotides or 20 nucleotides long.
The above said nucleic acid sequence being at least 10 nucleotides long, or the primer or probe, may further be at least 95 %, even more preferred 99% identical with the sequence SEQ ID No 2-12, or any sequences being complementary to SEQ ID No 2-12.
According to another aspect of the invention, a method for detection of a virus in a biological sample is provided. The method comprises the following steps:
a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,
b) subjecting the mixture of a) to a polymerase chain reaction with a primer pair, wherein each primer of said primer pair comprises at least 10 nucleotides and hybridizes to a nucleic acid sequence selected from the group consisting of SEQ ID No 4-12, sequences being complementary to SEQ ID No 4-12, and variants being at least 90 % identical with any of the sequences,
c) determining whether the binding of the nucleotide sequences to nucleotide sequences in the biological sample and amplification of the sequence between them have occurred indicating the presence of virus in the sample tested.
In a preferred embodiment, the primers of the method above are selected from a group consisting for SEQ ID No 4-12, preferably SEQ ID NO 7-12.
In step b) of the method above, the primers may further hybridize to a nucleic acid being at least 95 % or 100 % identical with the sequences SEQ ID No 4-12, or any sequences being complementary to SEQ ID No 4-12.
According to another aspect of the invention, another method for detection of a virus in a biological sample is provided. The method comprises the following steps: a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,
b) sequencing the mixture of a), and
c) comparing the resulting sequence with a sequence selected of the group consisting of SEQ ID No 2 and 3 and sequences being complementary to SEQ ID NO 2 and 3, wherein 70 % identity indicates the presence of virus in the biological sample tested.
Further, in step c) of the method above, 80 %, 90%, 95% or 100 % identity may be required to confirm the presence of virus in the biological sample.
In a preferred embodiment, the sequencing of the mixture in the method above is performed by a method selected from the group consisting of Next Generation Sequencing, preferably Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent or SOLiD sequencing (Goodwin S, et al., (2016) Coming of age: Ten years of next-generation sequencing technologies. Nature reviews, Genetics, 17, 333-351).
The invention also relates to use of a nucleic acid sequence comprising at the least 10 contiguous nucleotides of any of the sequences 2-12, or 10 contiguous nucleotides being complementary of any of the sequences 2-12, for confirming the presence of the virus in a biological sample. In yet another embodiment it is used a nucleic acid sequence having a sequence selected from the group of SEQ ID No 2 and 3 and sequences being complementary to the any of the sequences SEQ ID No 2 and 3.
The methods and uses above may be used to confirm that the virus is present in the biological samples, but it may also be used to confirm that the virus is not present in the biological samples. Further, it may be used to monitor a fish population, for instance for disease/sickness control. Information in this regard, desirable with methods for identifying other diseases and/or sicknesses, may be valuable information as to if or when the fish population should be treated. The biological samples to be analysed are preferably from dead fish, but may also be samples removed from live fish without harming the fish.
Another aspect of the invention relates to a vector comprising nucleic acid sequences according to the present invention, and host cells comprising said vectors.
According to yet another aspect of the invention, DNA vaccines are provided comprising a nucleic acid sequence selected from the group consisting of SEQ ID No. 2 and 3, sequences being complementary to sequences of SEQ ID No 2 and 3, and variants thereof being at least 70% identical with any of the sequences SEQ ID No. 2 and 3 or sequences being complementary to variants of SEQ ID No 2 and 3.
The nucleic acid sequence of the DNA vaccine may further be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 and 3, or any sequences being complementary to SEQ ID No 2 and 3.
Another aspect of the invention relates to recombinant proteins encoded by a nucleic acid sequence selected from the group consisting of SEQ ID No.2 and 3, and variants thereof being at least 70 %, 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No.2 and 3. In one aspect the amino acid sequence of the recombinant protein is given in SEQ ID No 1.
The present invention also provides a recombinant vaccine comprising at least one of the recombinant proteins according to the present invention.
The immunogenic composition may further comprise at least one excipient, additive or adjuvant, and may be administrated orally, by immersion or by injection.
Furthermore, according to another aspect of the invention, it is provided an antibody that recognises and binds to a recombinant protein according to the present invention.
The invention also relates to a diagnostic kit, which may be used to decide whether a sample comes from an organism being infected by the virus according to the invention.
Finally, the present invention relates to the use of the nucleic acid sequences having a sequences selected from the group consisting of SEQ ID NO 2 and 3, sequences being complementary to SEQ ID NO 2 and 3, and variants thereof being at least 70 %, 80 %, preferably 90%, more preferably 95 % identical with any of these sequences, for the preparation of DNA vaccine, recombinant vaccine or a live recombinant microorganism.
The present invention relates to isolated nucleic acid sequences and variants thereof being at least 70% identical with the isolated nucleic acid sequences. The term "% identity" is to be understood to refer to the percentage of nucleotides that two or more sequences or fragments thereof contains that are the same. The term "at least 70 % identical" thus means that at least 70 % of the nucleotides over the entire sequences which are compared, are identical. A specified percentage of nucleotides can be referred to as e.g. 70% identical, 80% identical, 85% identical, 90% identical, 95% identical, 99% identical or more over a specified region when compared and aligned for maximum correspondence. The skilled person will acknowledge that various means for comparing sequences are available.
The term "variants thereof" used in respect of the nucleic acid sequences and recombinant proteins according to the present invention, is to be understood to encompass nucleic acid sequences and recombinant proteins that only differs from the isolated sequences SEQ ID No.1, 2, and 3 by way of some amino acid or nucleotide additions, deletions or alteration that have little effect, if any, on the functional activity of the claimed sequences. The skilled person will acknowledge that modifications of a protein coding nucleotide sequence may be introduced which does not alter the amino acid sequence, e.g. the substitution of a nucleotide resulting in that the triplett affected by the substitution still codes for the same amino acid.
Such alterations may be introduced to adapt the nucleic acid sequence to the codons preferably used by a host cell and thus to enhance the expression of a desired recombinant protein. Furthermore, the addition of nucleic acid sequences coding polypeptides which facilitates purification may be added without affecting the activity of the resulting recombinant protein.
The skilled person will further acknowledge that also alterations of the nucleic acid sequence resulting in modifications of the amino acid sequence of the recombinant protein it codes may have little, if any, effect on e.g. the proteins' ability to induce protection against the virus if the alteration does not have any impact on the resulting three dimensional structure of the recombinant protein. For example, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a recombinant protein with substantially the same functional activity as the protein encoded by the nucleotide sequence SEQ ID No.2 or 3 and thus to be expected to constitute a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal or C-terminal portions of the protein molecule would also not be expected to alter the functional activity of the protein. Each of the proposed modifications is well within the routine skills in the art, as is determination of retention of biological activity of the encoded products. Therefore, where the terms "nucleic acid sequences of the invention" or "recombinant protein of the invention" are used in either the specification or the claims each will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent protein.
Thus, the present invention encompasses recombinant proteins and variants thereof which differ in respect of amino acid substitutions, addition or deletions compared with the protein of SEQ ID No 1, and proteins being encoded by the sequence SEQ ID No.2 or 3.
The primers and probes according to the present invention, will hybridize under stringent conditions with the sequence in question. The term “hybridizing under stringent conditions” refers to conditions of high stringency, i.e. in term of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. With “high stringency” conditions, nucleic acid base pairing will occur only between nucleic acids having a high frequency of complementary base sequences. Stringent hybridization conditions are known to the skilled person (see e.g. Green M. R., Sambrook, J., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 4th edition, 2012).
The precise conditions for stringent hybridization are typically sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.
The term "antigen" when used in connection with the present invention is to be understood to refer to a recombinant protein or fragment thereof according to the invention being able to induce protection against the virus in fish or to be able to bind to an antibody which recognise and bind to the virus.
The term "vaccine" as used herein refers to a material that can produce an immune response that blocks the infectivity, either partially or fully, of an infectious agent, which in respect of the present invention is the virus affecting fish such as e.g. salmonids. Thus, when administering the vaccines of the invention to a fish, the fish becomes immunised against the disease caused by the virus. The immunising component of the vaccine may be e.g. DNA as in a DNA vaccine, RNA as in a RNA vaccine, a recombinant protein or fragment thereof according to the present invention, or a live recombinant microorganism. The vaccines may be administered by immersion, orally or by injection.
The present invention also provides short nucleotide sequences having a length of at least 10 nucleotides. These sequences may be primers or probes useful in polymerase chain reaction techniques to be used as diagnostic tools. The terms "primer" and "probes" as used herein refers to an oligonucleotide either naturally occurring or produced synthetically which is significantly complementary to a virus target sequence and thus capable of hybridizing to nucleic acid sequences of the present invention. When a primer pair is used, it is generally one forward and one reverse primer, and the sequence between the primers will be multiplied during a PCR. This is well known to a skilled person, and he/she would know which primers constitute a suitable pair. The amplified sequence may be labelled to facilitate detection, e.g. using fluorescent labels on a probe, or other label means well known to the skilled person.
Figures
The invention will now be described in detail with reference to the enclosed Figures, where
Figure 1 shows the cumulated mortality of infected fish during 2017,
Figure 2 shows the amino acid sequence encoded by SEQ ID No.3, the amino acid sequence is corresponding to SEQ ID No 1,
Figure 3 shows the genomic sequence of the novel virus (PV) corresponding to SEQ ID No.2,
Figure 4 shows the genomic sequence of the CDS of the novel virus (PV), corresponding to SEQ ID No. 3,
Figure 5 shows the genomic sequence of PV1P corresponding to SEQ ID No.4, Figure 6 shows the genomic sequence of PV2P corresponding to SEQ ID No.5, Figure 7 shows the genomic sequence of PV3P corresponding to SEQ ID No.6, Figure 8 shows the genomic sequence of PV1F corresponding to SEQ ID No.7, Figure 9 shows the genomic sequence of PV2F corresponding to SEQ ID No.8, Figure 10 shows the genomic sequence of PV3F corresponding to SEQ ID No.9, Figure 11 shows the genomic sequence of PV1R corresponding to SEQ ID No.10, Figure 12 shows the genomic sequence of PV2R corresponding to SEQ ID No.11, and
Figure 13 shows the genomic sequence of PV3R corresponding to SEQ ID No.12.
Examples
Reference throughout the description to "an embodiment" signifies that a particular feature, structure or property specified in connection with an embodiment is included in the least in one embodiment. The expressions "in one embodiment", "in a preferred embodiment" or "in an alternative embodiment" different places in the description does not necessarily point to the same embodiment. Further, the different features, structures or properties may be combined in any suitable way in one or more of the embodiments.
Disease outbreak
A group of 70000 Atlantic salmon were stocked in sea water October 1<st>2016 at a commercial fish farm. Some mortality was observed during stocking, but the mortality was low in the period from March 2017 through June 2017. From June 2017 the mortality increased steadily. In September 2017, the mortality had reached more than 75% (Figure 1).
The fish showed symptoms of severe anaemia.
Tissue:
RNA sequencing and virus detection
On the day of slaughter, 2 September 2017, samples from gill, heart and kidney were collected from 10 fish, from the outbreak above, and sent to PatoGen for analysis by Real-Time qPCR. The samples were analysed for Paramoeba perurans, Branchiomonas, Piscine Reovirus (PRV), Pancreas Disease Virus (PDV), Paranucleospora theridion, Pravicapsula pseudobranchicola, Salmon gill poxvirus (SGPVD), Tenacibaculum maritimum, Yersinia ruckeri, Pasteurella skyensis, Piscirickettsia salmonis, and Infectious Pancreatic Necrosis Virus (IPNV) (Table 1). Although the gills were particularly affected by many agents, none of the detected agents could explain the observed anaemia and mortality, considering the symptoms and the results of the analysis.
np=not performed; nd=no data
Number of samples analysed (N)=10 except for * where N=1, **N=2, ***N=7
Tissue preparation, RNA isolation and analysis
RNA was extracted from samples of kidney, heart and gills using RNAeasy Universal kit (Qiagen) on an automated system at the PatoGen AS accredited commercial laboratory. The RNA quality and concentration of the samples were assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies) and the Qubit 3.0 Fluorometer (Thermo Fischer scientific) using the RNA 6000 Pico Kit (Agilent) and the Qubit<TM>RNA HS Assay kit (Thermo Fischer Scientific).
Library preparation and RNA sequencing with Ion Torrent S5
3,2 µg of RNA from one gill sample was used as starting input for the RNA sequencing library preparation. The RNA from the sample was treated with RiboMinus TM Eukaryote Kit v2 (Thermo Fischer Scientific) to remove ribosomal RNA. The rRNA-depleted RNA was fragmented and library was constructed using the Ion Total-RNA Seq Kit v2 (Thermo Fischer Scientific). The library was bar-coded and further quantified with qRT-PCR.
Using the Ion Chef and the Ion 520<TM>and Ion 530<TM>kit Chef (Thermo Fischer Scientific), the library was clonally amplified on Ion Sphere Particles, loaded into one 530 Chip and sequenced on the Ion Torrent S5 (Thermo Fischer Scientific).
Description of bioinformatics analysis
Approximately five million reads were generated for the RNA sequencing experiment. BAM-files were converted to FASTQ files using SAMTOOLS fastq command, and we applied our in-house pathogen detection pipeline using the reads. Our approach utilizes publicly available research tools, as described in the following.
First, reads were first trimmed 25bp in both the 5’ and 3’ end, and short reads (<10 bps) were removed using VSEARCH (https://github.com/torognes/vsearch). Reads mapping to the salmon genome were then removed using Kraken (Wood and Salzberg, 2014), before sequence construction with SPADES using the remaining reads were performed (Bankevich et al., 2012). The resulting scaffold sequences were then tested for complementarity with known sequences using blastn and blastx algorithms against the nucleotide (nt) and Swiss-Prot databases, respectively.
The obtained sequence matched partly to members of the Picornaviridae family (Posavirus and Fisavirus).
The final genome is 8,713 bps, and divided into the following sections;
Bases 1-602; 5’UTR
Bases 603-8,585; CDS (2661 aa)
Bases 8,586-8,713; 3’UTR
Real Time PCR
To validate if the tentative virus, in the following referred to as PV, could be disease causing we designed a RT-PCR-assay in the presumptive polymerase region of the sequence using forward and reverse primers (PV1-F and PV1-R table 4 and 5), and a minor groove binding (MGB) probe (PV1-P) labelled with 6-FAM (table 3). The primers were designed using the software Primer Express 3.0.1 (Thermo Fischer Scientific). Secondary structures and the possibility of primer dimers were tested using the online software IDT OligoAnalyzer 3.1, and the specificity of the primers and the probe were checked using NCBI’s Blastn. The primers and the probe were found not to form secondary structures or primer dimers, nor to hybridize to any other known sequence. The primers and the probe were manufactured by Thermo Fischer Scientific.
The RT-PCR assay was performed using TaqMan® Fast Virus 1-Step Master Mix. Amplifications were done on a QuantStudio 5 Real Time PCR systemThermo Fischer Scientific) with the following conditions: 5 min at 50 °C, 20 sec at 95 °C followed by 45 cycles of 95 °C/3 sec and 60 °C/30 seconds.
Results of the qPCR
To validate if the tentative virus could be disease causing, 11 fish with clinical symptoms, and 16 fish with no symptoms were tested with the PV1- qPCR assay (Table 2). Extracted total RNA from gill, kidney or heart samples were used in the test.
-----" means negative result of detection.
The PV1 Real Time assay detected relatively high amounts of the gene sequence the PV assay targeted. There are multiple factors that may have affected the fish, however the overall trends is clear positive, and samples from the gills of all fish having clinical symptoms, were positive with Ct values ranging from 16,2 to 29,8. The gill tissue from fish with no symptoms of disease were in general negative to PV1 by Real Time assay, except for two fish that had Ct values of 35,4 and 37 which show that there are very small amount of virus detected in these fish. This confirms that the virus detected causes the observed symptoms of anaemia.
Additional qPCR assays
We have designed 3 quantitative Real Time TaqMan assays targeting various regions of the genome, as described above for PV1.
Virus stability
The virus was passed through cell lines as described 10 times, and the virus did not change.
Virulence of the virus
Juvenile Atlantic salmon were challenged to a suspension of the virus, in freshwater, under standard conditions. High mortality was observed.
Claims (17)
1. An isolated nucleic acid sequence originating from a virus in Atlantic salmon having a sequence selected from the group consisting of SEQ ID No 2 and 3, sequences being complementary to SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical thereof.
2. An isolated nucleic acid sequence according to claim 1, characterized in that the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 or 3, or any sequences being complementary to SEQ ID No 2 or 3.
3. A primer and/or probe having a sequence selected from the group consisting of SEQ ID NO 4-12, sequences being complementary to SEQ ID NO 4-12, and variants being at least 90 % identical with any of the sequences SEQ ID NO 4-12 and sequences being complementary to variants of SEQ ID NO 4-12.
4. A method for detection of a virus in a biological sample, characterized by comprising the following steps:
a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,
b) subjecting the mixture of a) to a polymerase chain reaction with a pair of primers according to claim 3, and
c) determining whether the binding of the primers to nucleotide sequences in the sample and amplification of the sequence between them have occurred indicating the presence of the virus in the sample tested.
5. A method for detection of a virus in a biological sample, characterized by comprising the following steps:
a) preparing a sample comprising nucleic acid sequences isolated from the biological sample for a reverse transcription reaction,
b) sequencing the mixture of a), and
c) comparing the resulting sequence with the sequence selected of the group consisting of SEQ ID No 2 and 3 and sequences being complementary to SEQ ID NO 2 and 3, wherein at least 70 % identity verifies the presence of the virus in the biological sample tested.
6. A method according to claim 5, wherein the sequencing is performed by a method selected from the group consisting in Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.
7. A method according to 5 or 6, wherein the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 2 and 3 or sequences being complementary to SEQ ID No 2 and 3.
8. Use of a nucleotide sequence comprising at the least 10 contiguous nucleotides of any of the sequences SEQ ID No 2-12, or 10 contiguous nucleotides being complementary of any of the sequences SEQ ID No 2-12, for establishing the existence of virus in a biological sample.
9. Use according to claim 8, wherein the nucleic acid sequence has a sequence selected from the group of SEQ ID No 2 and 3, or a sequence being complementary to the any of the sequences SEQ ID No 2 and 3.
10. A vector comprising a nucleic acid sequence according to any one of claims 1-2.
11. A host cell comprising a vector according to claim 10.
12. A DNA-vaccine comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 2 and 3.
13. A recombinant protein encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO 2 and 3, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 2 and 3.
14. A recombinant protein having an amino acid sequence according to SEQ ID No 1.
15. A recombinant vaccine comprising at least one recombinant protein according to claim 13 or 14.
16. An antibody specifically recognizing and specifically binding to a recombinant protein according to claim 12 or 13.
17. Diagnostic kit comprising at least one primer sequence according to claim 3.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20180836A NO344698B1 (en) | 2018-06-15 | 2018-06-15 | Novel fish virus |
PCT/NO2019/050124 WO2019240596A1 (en) | 2018-06-15 | 2019-06-14 | Novel fish virus |
EP19737262.6A EP3807403A1 (en) | 2018-06-15 | 2019-06-14 | Novel fish virus |
CA3103433A CA3103433A1 (en) | 2018-06-15 | 2019-06-14 | Novel fish virus |
CL2020003238A CL2020003238A1 (en) | 2018-06-15 | 2020-12-14 | New fish virus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20180836A NO344698B1 (en) | 2018-06-15 | 2018-06-15 | Novel fish virus |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20180836A1 NO20180836A1 (en) | 2019-12-16 |
NO344698B1 true NO344698B1 (en) | 2020-03-09 |
Family
ID=67211790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20180836A NO344698B1 (en) | 2018-06-15 | 2018-06-15 | Novel fish virus |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3807403A1 (en) |
CA (1) | CA3103433A1 (en) |
CL (1) | CL2020003238A1 (en) |
NO (1) | NO344698B1 (en) |
WO (1) | WO2019240596A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045543A2 (en) * | 2002-11-14 | 2004-06-03 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2012066481A1 (en) * | 2010-11-15 | 2012-05-24 | Pharmaq As | New ethiological agent |
US20130045873A1 (en) * | 2005-01-27 | 2013-02-21 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035680A1 (en) * | 2001-10-19 | 2003-05-01 | Akzo Nobel N.V. | Infectious salmon anaemia virus vaccine |
WO2016075277A1 (en) * | 2014-11-14 | 2016-05-19 | Patogen Analyse As | Novel fish virus and method for detection |
-
2018
- 2018-06-15 NO NO20180836A patent/NO344698B1/en unknown
-
2019
- 2019-06-14 CA CA3103433A patent/CA3103433A1/en active Pending
- 2019-06-14 EP EP19737262.6A patent/EP3807403A1/en active Pending
- 2019-06-14 WO PCT/NO2019/050124 patent/WO2019240596A1/en active Application Filing
-
2020
- 2020-12-14 CL CL2020003238A patent/CL2020003238A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045543A2 (en) * | 2002-11-14 | 2004-06-03 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20130045873A1 (en) * | 2005-01-27 | 2013-02-21 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
WO2012066481A1 (en) * | 2010-11-15 | 2012-05-24 | Pharmaq As | New ethiological agent |
Also Published As
Publication number | Publication date |
---|---|
EP3807403A1 (en) | 2021-04-21 |
NO20180836A1 (en) | 2019-12-16 |
WO2019240596A1 (en) | 2019-12-19 |
CL2020003238A1 (en) | 2021-06-11 |
CA3103433A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roohani et al. | Characterisation of genotype VII Newcastle disease virus (NDV) isolated from NDV vaccinated chickens, and the efficacy of LaSota and recombinant genotype VII vaccines against challenge with velogenic NDV | |
Gong et al. | Genome-wide characterization of Toll-like receptor gene family in common carp (Cyprinus carpio) and their involvement in host immune response to Aeromonas hydrophila infection | |
Lei et al. | Difference between hemocyanin subunits from shrimp Penaeus japonicus in anti-WSSV defense | |
Whang et al. | Characterization and expression analysis of a goose-type lysozyme from the rock bream Oplegnathus fasciatus, and antimicrobial activity of its recombinant protein | |
Gjerde | Sarcocystis species in red deer revisited: with a re-description of two known species as Sarcocystis elongata n. sp. and Sarcocystis truncata n. sp. based on mitochondrial cox1 sequences | |
Nguyen et al. | Identification and expression analysis of two pro-inflammatory cytokines, TNF-α and IL-8, in cobia (Rachycentron canadum L.) in response to Streptococcus dysgalactiae infection | |
Bellière et al. | Genetic comparison among dolphin morbillivirus in the 1990–1992 and 2006–2008 Mediterranean outbreaks | |
WO2009098789A1 (en) | Method of detecting pathogenic virus in crustacean by lamp method and reagent kit for detection | |
Fellahi et al. | Phylogenetic analysis of avian infectious bronchitis virus S1 glycoprotein regions reveals emergence of a new genotype in Moroccan broiler chicken flocks | |
WO2018203757A1 (en) | Novel virus in fish and a method for detection | |
Mao et al. | Avian leukosis virus contamination in live vaccines: a retrospective investigation in China | |
Chen et al. | Full-length transcriptome sequencing and identification and immune response of TRIM genes in Dabry's sturgeon (Acipenser dabryanus) | |
Shen et al. | Molecular cloning, characterization and expression of the complement component Bf/C2 gene in grass carp | |
Thakor et al. | Molecular characterization of avian adeno virus causing inclusion body hepatitis–hydropericardium syndrome in broiler chickens of Anand, Gujarat, India | |
Tang et al. | Expression and functional characterization of interferon regulatory factors 4, 8, and 9 in large yellow croaker (Larimichthys crocea) | |
GB2377017A (en) | Detection of foot and mouth disease virus | |
Abernathy et al. | Gene expression profiling of a fish parasite Ichthyophthirius multifiliis: Insights into development and senescence-associated avirulence | |
NO344698B1 (en) | Novel fish virus | |
Yeh et al. | EcVig, a novel grouper immune-gene associated with antiviral activity against NNV infection | |
Wang et al. | Identification of immune‐related genes from kidney and spleen of turbot, Psetta maxima (L.), by suppression subtractive hybridization following challenge with Vibrio harveyi | |
Godahewa et al. | Complement factor D homolog involved in the alternative complement pathway of rock bream (Oplegnathus fasciatus): Molecular and functional characterization and immune responsive mRNA expression analysis | |
KR20150110531A (en) | High resolution melt genotyping od ibv, csfv and ndv | |
Barghash | Molecular changes in Trypanosoma evansi after treatment against trypanosomosis | |
KR101617142B1 (en) | Nucleic acid test based avian influenza virus detection kit with improved detection accuracy | |
NO20201187A1 (en) | Novel fish virus |